Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 21Myeloid 14Lymphoid 13Plasma cell 12Classical hematology 6CNS 6Other solid neoplasm 4Gastrointestinal 3Sarcoma 1Other neoplasm 1Dermatologic 1Breast 1

Conditions

Venentoclax 1

Interventions

Magnetic Resonance Spectroscopy 3Biopsy 3fludarabine 2Taxes 2Paclitaxel 2Endoscopic Mucosal Resection 2Aminolevulinic Acid 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2venetoclax 1trametinib 1toripalimab 1thymoglobulin 1taxane 1sintilimab 1potassium oxonate 1lutetium Lu 177 dotatate 1gimeracil 1fludarabine phosphate 1dabrafenib 1apatinib 1Whole-Body Irradiation 1Watchful Waiting 1Transurethral Resection of Prostate 1Tegafur 1Surgical Procedures, Operative 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Melphalan × Other neoplasm × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡